Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články
PubMed
35076937
DOI
10.1111/bjh.18073
Knihovny.cz E-zdroje
- Klíčová slova
- 3rd dose, COVID-19, coronavirus, haematological oncology, vaccination, vaccine,
- MeSH
- COVID-19 * prevence a kontrola MeSH
- hematologické nádory * terapie MeSH
- lidé MeSH
- protilátky virové MeSH
- SARS-CoV-2 MeSH
- tvorba protilátek MeSH
- vakcína BNT162 MeSH
- vakcíny proti COVID-19 MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- protilátky virové MeSH
- vakcína BNT162 MeSH
- vakcíny proti COVID-19 MeSH
We have vaccinated 392 patients with two doses of mRNA COMIRNATY vaccine with an overall antibody response of 70% (best in cMPN, worst in CLL). We have then vaccinated 80 patients who did not achieve seroconversion or were low responders with a third dose of COMIRNATY vaccine. Our first results show promise, especially for patients on anti-CD38 therapy.
Department of Haemato oncology University Hospital Ostrava Ostrava Czech Republic
Faculty of Medicine University of Ostrava Ostrava Czech Republic
Zobrazit více v PubMed
Piñana JL, Martino R, García-García I, Parody R, Morales MD, Benzo G, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol [Internet]. 2020;9(1):21. https://doi.org/10.1186/s40164-020-00177-z
De Ramón C, Hernandez-Rivas JA, Rodríguez García JA, Ocio EM, Gómez-Casares MT, López Jiménez J, et al. Impact of SARS-CoV2 infection on 491 hematological patients: the ecovidehe multicenter study. Blood [Internet]. 2020;136(Supplement 1):5-6. https://doi.org/10.1182/blood-2020-142292
Šimánek V, Pecen L, Krátká Z, Fürst T, Řezáčková H, Topolčan O, et al. Five commercial immunoassays for SARS-CoV-2 antibody determination and their comparison and correlation with the virus neutralization test. Diagnostics (Basel) [Internet]. 2021;11(4):593. https://doi.org/10.3390/diagnostics11040593
Krátká Z, Fejt V, Kučera R, Fürst T, Zelená H. Antibodies from previous infection bring sufficient and long-term protection against COVID-19. Cas Lek Cesk. 2021;160(5):167-75.
R: A Language and Environment for Statistical Computing. R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/.
Tran S, Truong TH, Narendran A. Evaluation of COVID-19 vaccine response in patients with cancer: an interim analysis. Eur J Cancer [Internet]. 2021;159:259-74. https://doi.org/10.1016/j.ejca.2021.10.013
Van Oekelen O, Gleason CR, Agte S, Srivastava K, Beach KF, Aleman A, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell [Internet]. 2021;39(8):1028-30. https://doi.org/10.1016/j.ccell.2021.06.014
Shah Mansi R., Gabel A, Beers S, Salaru G, Lin Y, Cooper DL. COVID-19 vaccine responses inpatients with plasma cell dyscrasias after complete vaccination. Clin Lymphoma Myeloma Leuk. 2021; http://dx.doi.org/10.1016/j.clml.2021.11.001. Epub ahead of print.
Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J [Internet]. 2021;11(8):138. https://doi.org/10.1038/s41408-021-00530-3
Roeker LE, Knorr DA, Thompson MC, Nivar M, Lebowitz S, Peters N, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia [Internet]. 2021;35(9):2703-5. https://doi.org/10.1038/s41375-021-01270-w
Tadmor T, Benjamini O, Braester A, Rahav G, Rokach L. Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia. Leukemia [Internet]. 2021;35(9):2727-30. https://doi.org/10.1038/s41375-021-01380-5
Herishanu Y, Rahav G, Levi S, Braester A, Itchaki G, Bairey O, et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard two-dose vaccination. Blood [Internet]. 2021;139(5):678-85. https://doi.org/10.1182/blood.2021014085
Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, et al. Booster BNT162b2 optimizes SARS-CoV-2 humoral response in myeloma patients; The negative effect of anti-BCMA therapy. Blood [Internet]. 2022. https://doi.org/10.1182/blood.2021014989. Online ahead of print.
Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, et al. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European myeloma network. Lancet Haematol [Internet]. 2021;8(12):e934-46. https://doi.org/10.1016/S2352-3026(21)00278-7
Sun C, Pleyer C, Wiestner A. COVID-19 vaccines for patients with haematological conditions. Lancet Haematol [Internet]. 2021;8(5):e312-4. https://doi.org/10.1016/S2352-3026(21)00073-9
ESMO. ESMO Statements on vaccination against COVID-19 in people with cancer [Internet]. Esmo.org. [cited 2022 Jan 17]. https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination
